Progenics Pharma (PGNX) Misses Q3 EPS by 1c

Progenics Pharma (NASDAQ: PGNX) reported Q3 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $2.35 million.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold